Similarly, AZD1775 synergized with Doxorubicin, a topoisomerase II inhibitor, in P53-mutated colon cancer cell lines, enhancing its cytotoxicity and efficacy (Hirai et al. 2010). This evidence concerns the gene TP53 and malignant colon neoplasm.